Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a clinical history of mild to moderate asthma for at least 6 months, but otherwise is in good health~* Participant with allergic rhinitis and asthma has a history of nonseasonal airway symptoms in response to aeroallergens OR has seasonal symptoms but can be evaluated out-of-season~* Is clinically stable and free of respiratory infection or change in allergen exposure for at least 4 weeks prior to start of study~Exclusion Criteria:~* Has intolerance to the study drug, inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication~* Has intolerance to lidocaine/lignocaine, sedatives, atropine or glycopyrrolate, or any other medication associated with bronchoscopy~* Has taken oral parenteral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 5 weeks of screening and/or during the study~* Has recent (4 weeks) or ongoing upper or lower respiratory tract infection~* Has active allergic rhinitis at screening~* Has received a vaccination within 3 weeks of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone, then Placebo (Type: EXPERIMENTAL): Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
- Placebo, then Prednisone (Type: EXPERIMENTAL): Placebo in the first crossover treatment period and prednisone in the second crossover treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).